![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China which includes Ebrantil®.
Lead Product(s): Urapidil Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ebrantil
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hasten
Deal Size: $322.0 million Upfront Cash: Undisclosed
Deal Type: Divestment December 21, 2020